Mechanisms of action and resistance in histone methylation-targeted therapy.

Adult Humans Chromatin / chemistry DNA Methylation / drug effects Drug Resistance, Neoplasm / drug effects Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors Epigenesis, Genetic / drug effects Genes, Tumor Suppressor / drug effects Histones / chemistry Homeostasis / drug effects Leukemia-Lymphoma, Adult T-Cell / drug therapy Lysine / chemistry Methylation / drug effects Mutation Polycomb Repressive Complex 2 / genetics Single-Cell Analysis

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 06 07 2022
accepted: 23 01 2024
medline: 8 3 2024
pubmed: 22 2 2024
entrez: 21 2 2024
Statut: ppublish

Résumé

Epigenomes enable the rectification of disordered cancer gene expression, thereby providing new targets for pharmacological interventions. The clinical utility of targeting histone H3 lysine trimethylation (H3K27me3) as an epigenetic hallmark has been demonstrated

Identifiants

DOI: 10.1038/s41586-024-07103-x PMID: 38383791 PMC: PMC10917674
pubmed: 38383791
doi: 10.1038/s41586-024-07103-x
pii: 10.1038/s41586-024-07103-x
pmc: PMC10917674
doi:

Substances chimiques

Chromatin 0
DNMT3A protein, human 0
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
EZH1 protein, human EC 2.1.1.43
EZH2 protein, human EC 2.1.1.43
Histones 0
Lysine K3Z4F929H6
Polycomb Repressive Complex 2 EC 2.1.1.43
TET2 protein, human EC 1.13.11.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-228

Informations de copyright

© 2024. The Author(s).

Références

Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349 (2011).
pubmed: 21248841 pmcid: 3760771 doi: 10.1038/nature09784
Yamagishi, M. & Uchimaru, K. Targeting EZH2 in cancer therapy. Curr. Opin. Oncol. 29, 375–381 (2017).
pubmed: 28665819 doi: 10.1097/CCO.0000000000000390
Bhat, K. P., Kaniskan, H. U., Jin, J. & Gozani, O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat. Rev. Drug Discov. 20, 265–286 (2021).
pubmed: 33469207 pmcid: 8035164 doi: 10.1038/s41573-020-00108-x
Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433–1442 (2020).
pubmed: 33035457 pmcid: 8427481 doi: 10.1016/S1470-2045(20)30441-1
Gounder, M. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21, 1423–1432 (2020).
pubmed: 33035459 doi: 10.1016/S1470-2045(20)30451-4
Morishima, S. et al. First-in-human study of the EZH1/2 dual inhibitor valemetostat in relapsed or refractory non-Hodgkin lymphoma (NHL) — updated results focusing on adult T-cell leukemia-lymphoma (ATL). Blood 134, 4025 (2019).
doi: 10.1182/blood-2019-125507
Izutsu, K. et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood 141, 1159–1168 (2023).
pubmed: 36150143 doi: 10.1182/blood.2022016862
Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503–518 (2008).
pubmed: 19026781 pmcid: 3641558 doi: 10.1016/j.molcel.2008.11.004
Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491–502 (2008).
pubmed: 19026780 pmcid: 2630502 doi: 10.1016/j.molcel.2008.10.016
Yamagishi, M. et al. Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas. Cell Rep. 29, 2321–2337.e7 (2019).
pubmed: 31747604 doi: 10.1016/j.celrep.2019.10.083
Honma, D. et al. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 108, 2069–2078 (2017).
pubmed: 28741798 pmcid: 5623739 doi: 10.1111/cas.13326
Katsuya, H. et al. Treatment and survival among 1594 patients with ATL. Blood 126, 2570–2577 (2015).
pubmed: 26361794 doi: 10.1182/blood-2015-03-632489
Cook, L. B. et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J. Clin. Oncol. 37, 677–687 (2019).
pubmed: 30657736 pmcid: 6494249 doi: 10.1200/JCO.18.00501
Yamagishi, M. et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 21, 121–135 (2012).
pubmed: 22264793 doi: 10.1016/j.ccr.2011.12.015
Fujikawa, D. et al. Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127, 1790–1802 (2016).
pubmed: 26773042 doi: 10.1182/blood-2015-08-662593
Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47, 1304–1315 (2015).
pubmed: 26437031 doi: 10.1038/ng.3415
Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402–406 (2016).
pubmed: 27281199 doi: 10.1038/nature18294
Yamagishi, M. et al. Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma. Nat. Commun. 12, 4821 (2021).
pubmed: 34376672 pmcid: 8355240 doi: 10.1038/s41467-021-25101-9
Kataoka, K. et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood 131, 215–225 (2018).
pubmed: 29084771 pmcid: 5757690 doi: 10.1182/blood-2017-01-761874
Kobayashi, S. et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 20, 2851–2861 (2014).
pubmed: 24727323 doi: 10.1158/1078-0432.CCR-13-3169
Cai, Y. et al. H3K27me3-rich genomic regions can function as silencers to repress gene expression via chromatin interactions. Nat. Commun. 12, 719 (2021).
pubmed: 33514712 pmcid: 7846766 doi: 10.1038/s41467-021-20940-y
Zhao, M., Sun, J. & Zhao, Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res. 41, D970–D976 (2013).
pubmed: 23066107 doi: 10.1093/nar/gks937
Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487–500 (2016).
pubmed: 27346641 doi: 10.1038/nrg.2016.59
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Baker, T. et al. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget 6, 32646–32655 (2015).
pubmed: 26360609 pmcid: 4741719 doi: 10.18632/oncotarget.5066
Gibaja, V. et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 35, 558–566 (2016).
pubmed: 25893294 doi: 10.1038/onc.2015.114
O’Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412 (2009).
pubmed: 19878872 pmcid: 2804470 doi: 10.1016/j.ccr.2009.09.028
Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431–443 (2019).
pubmed: 31543464 pmcid: 6893878 doi: 10.1016/j.ccell.2019.08.004
Shah, M. et al. A transcript-specific eIF3 complex mediates global translational control of energy metabolism. Cell Rep. 16, 1891–1902 (2016).
pubmed: 27477275 pmcid: 4988921 doi: 10.1016/j.celrep.2016.07.006
Lamper, A. M., Fleming, R. H., Ladd, K. M. & Lee, A. S. Y. A phosphorylation-regulated eIF3d translation switch mediates cellular adaptation to metabolic stress. Science 370, 853–856 (2020).
pubmed: 33184215 doi: 10.1126/science.abb0993
Lee, A. S. Y., Kranzusch, P. J., Doudna, J. A. & Cate, J. H. D. eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation. Nature 536, 96–99 (2016).
pubmed: 27462815 pmcid: 5003174 doi: 10.1038/nature18954
Thacker, J. S. et al. Unlocking the brain: a new method for western blot protein detection from fixed brain tissue. J. Neurosci. Methods 348, 108995 (2021).
pubmed: 33202258 doi: 10.1016/j.jneumeth.2020.108995
Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).
pubmed: 23992846 pmcid: 3856256 doi: 10.1016/j.cell.2013.08.021
Yuan, W. et al. Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation. Science 337, 971–975 (2012).
pubmed: 22923582 doi: 10.1126/science.1225237
Porazzi, P. et al. Targeting chemotherapy to decondensed H3K27me3-marked chromatin of AML cells enhances leukemia suppression. Cancer Res. 82, 458–471 (2022).
pubmed: 34903608 doi: 10.1158/0008-5472.CAN-21-1297
Boumahdi, S. & Sauvage, F. J. de The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39–56 (2020).
pubmed: 31601994 doi: 10.1038/s41573-019-0044-1
Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020).
pubmed: 33033407 doi: 10.1038/s41568-020-00302-4
Shimoyama, M. Diagnostic criteria and classification of clinical sub- types of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br. J. Haematol. 79, 428–437 (1991).
pubmed: 1751370 doi: 10.1111/j.1365-2141.1991.tb08051.x
Li, H. et al. The Sequence Alignment/Map (SAM) format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 pmcid: 3833702 doi: 10.1038/nbt.2514
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res. 38, e164 (2010).
pubmed: 20601685 pmcid: 2938201 doi: 10.1093/nar/gkq603
Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
pubmed: 24633410 pmcid: 4864026 doi: 10.1038/nmeth.2883
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).
doi: 10.14806/ej.17.1.200
Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next generation sequencing data. Bioinformatics 28, 423–425 (2012).
pubmed: 22155870 doi: 10.1093/bioinformatics/btr670
Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. & Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333–1341 (2021).
pubmed: 34725479 pmcid: 9255697 doi: 10.1038/s41592-021-01282-5
Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).
pubmed: 31740819 pmcid: 6884693 doi: 10.1038/s41592-019-0619-0
Lerdrup, M., Johansen, J. V., Agrawal-Singh, S. & Hansen, K. An interactive environment for agile analysis and visualization of ChIP-sequencing data. Nat. Struct. Mol. Biol. 23, 349–357 (2016).
pubmed: 26926434 doi: 10.1038/nsmb.3180
Ramírez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975 pmcid: 4987876 doi: 10.1093/nar/gkw257
Sakamoto, Y. et al. Long-read whole-genome methylation patterning using enzymatic base conversion and nanopore sequencing. Nucleic Acids Res. 49, e81 (2021).
pubmed: 34019650 pmcid: 8373077 doi: 10.1093/nar/gkab397
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for bisulfite-seq applications. Bioinformatics 27, 1571–1572 (2011).
pubmed: 21493656 pmcid: 3102221 doi: 10.1093/bioinformatics/btr167
Jühling, F. et al. metilene: Fast and sensitive calling of differentially methylated regions from bisulfite sequencing data. Genome Res. 26, 256–262 (2016).
pubmed: 26631489 pmcid: 4728377 doi: 10.1101/gr.196394.115
Robinson, J. T. et al. Integrative Genomics Viewer. Nat. Biotechnol. 29, 24–26 (2011).
pubmed: 21221095 pmcid: 3346182 doi: 10.1038/nbt.1754
Ge, S. X., Son, E. W. & Yao, R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-seq data. BMC Bioinformatics 19, 534 (2018).
pubmed: 30567491 pmcid: 6299935 doi: 10.1186/s12859-018-2486-6
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Wang, L. et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J. Am. Chem. Soc. 137, 2695–2703 (2015).
pubmed: 25625324 doi: 10.1021/ja512751q
Steinbrecher, T. et al. Predicting the effect of amino acid single-point mutations on protein stability-large-scale validation of MD-based relative free energy calculations. J. Mol. Biol. 429, 948–963 (2017).
pubmed: 27964946 doi: 10.1016/j.jmb.2016.12.007
Lu, C. et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17, 4291–4300 (2021).
pubmed: 34096718 doi: 10.1021/acs.jctc.1c00302
Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415 (2003).
pubmed: 12824337 pmcid: 169194 doi: 10.1093/nar/gkg595

Auteurs

Makoto Yamagishi (M)

Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. myamagishi@edu.k.u-tokyo.ac.jp.
Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. myamagishi@edu.k.u-tokyo.ac.jp.
ORCID: 0000-0002-8142-4686

Yuta Kuze (Y)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Seiichiro Kobayashi (S)

Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology, Kanto Rosai Hospital, Kanagawa, Japan.

Makoto Nakashima (M)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Satoko Morishima (S)

Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
ORCID: 0000-0002-7391-4271

Toyotaka Kawamata (T)

Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
ORCID: 0000-0003-1311-8756

Junya Makiyama (J)

Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology, Sasebo City General Hospital, Nagasaki, Japan.
ORCID: 0000-0003-0883-2920

Kako Suzuki (K)

Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Masahide Seki (M)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
ORCID: 0000-0001-6091-8698

Kazumi Abe (K)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Kiyomi Imamura (K)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Eri Watanabe (E)

IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Kazumi Tsuchiya (K)

IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Isao Yasumatsu (I)

Organic and Biomolecular Chemistry Department, Daiichi Sankyo RD Novare, Tokyo, Japan.
ORCID: 0009-0000-9865-4835

Gensuke Takayama (G)

Translational Science I, Daiichi Sankyo, Tokyo, Japan.

Yoshiyuki Hizukuri (Y)

Translational Science I, Daiichi Sankyo, Tokyo, Japan.

Kazumi Ito (K)

Translational Science I, Daiichi Sankyo, Tokyo, Japan.

Yukihiro Taira (Y)

Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Yasuhito Nannya (Y)

Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Arinobu Tojo (A)

Tokyo Medical and Dental University, Tokyo, Japan.
ORCID: 0000-0001-9016-1948

Toshiki Watanabe (T)

Department of Practical Management of Medical Information, Graduate School of Medicine, St Marianna University, Kanagawa, Japan.

Shinji Tsutsumi (S)

Translational Science I, Daiichi Sankyo, Tokyo, Japan.

Yutaka Suzuki (Y)

Laboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ysuzuki@edu.k.u-tokyo.ac.jp.
ORCID: 0000-0003-4852-1879

Kaoru Uchimaru (K)

Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. uchimaru@edu.k.u-tokyo.ac.jp.
Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. uchimaru@edu.k.u-tokyo.ac.jp.
ORCID: 0000-0002-1665-9606

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Chromatine › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines de répression › Protéines du groupe Polycomb › Complexe répresseur Polycomb-2 › Protéine-2 homologue de l'activateur de Zeste › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Histone › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes physiologiques › Homéostasie › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie à cellules T › Leucémie-lymphome à cellules T de l'adulte › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés essentiels › Lysine › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Métabolisme › Alkylation › Méthylation › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines de répression › Protéines du groupe Polycomb › Complexe répresseur Polycomb-2 › Mechanisms of action and resistance in histone...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Analyse sur cellule unique › Mechanisms of action and resistance in histone...